Get the Stockscreener App
4.31
2.05%
-0.09
Genelux Corp stock is traded at $4.31, with a volume of 102.15K.
It is down -2.05% in the last 24 hours and down -27.32% over the past month.
Genelux Corp is a clinical-stage biopharmaceutical company. The company focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive or difficult-to-treat solid tumor types. Its pipeline products include Olvi-Vec (olvimulogene nanivacirepvec), Lung, and Pancreatic Cancer.
See More
Previous Close:
$4.40
Open:
$4.4
24h Volume:
102.15K
Relative Volume:
0.45
Market Cap:
$164.00M
Revenue:
-
Net Income/Loss:
$-27.66M
P/E Ratio:
-4.5368
EPS:
-0.95
Net Cash Flow:
$-24.36M
1W Performance:
-7.11%
1M Performance:
-27.32%
6M Performance:
+62.64%
1Y Performance:
+71.03%
1-Day Range:
$4.165
$4.525
1-Week Range:
$4.165
$5.0201
52-Week Range:
$1.9875
$8.535
Genelux Corp Stock (GNLX) Company Profile
Name
Genelux Corp
Sector
Industry
Phone
805-267-9889
Address
2625 TOWNSGATE ROAD, SUITE 230, WESTLAKE VILLAGE
Compare GNLX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
GNLX
Genelux Corp
|
4.31 | 167.43M | 0 | -27.66M | -24.36M | -0.95 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.04 | 113.14B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
741.29 | 78.49B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
877.94 | 54.76B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
397.55 | 54.51B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
197.01 | 41.64B | 447.02M | -1.18B | -906.14M | -6.1812 |
Genelux Corp Stock (GNLX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-21-25 | Initiated | Lake Street | Buy |
| Oct-29-24 | Initiated | Guggenheim | Buy |
| Aug-28-24 | Initiated | ROTH MKM | Buy |
| Nov-27-23 | Initiated | H.C. Wainwright | Buy |
| Sep-12-23 | Initiated | Maxim Group | Buy |
| Feb-15-23 | Initiated | The Benchmark Company | Speculative Buy |
View All
Genelux Corp Stock (GNLX) Latest News
Cappello, Genelux CTO, sells $14k in GNLX stock By Investing.com - Investing.com Nigeria
Genelux (NASDAQ:GNLX) CEO Thomas Zindrick Sells 4,509 Shares - MarketBeat
Genelux (NASDAQ:GNLX) CEO Thomas Zindrick Sells 12,673 Shares of Stock - MarketBeat
Genelux SVP, Yu Yong, sells shares worth $16k By Investing.com - Investing.com Nigeria
Genelux president sells $66k in GNLX stock By Investing.com - Investing.com Australia
Cappello, Genelux CTO, sells $14k in GNLX stock - Investing.com
GENELUX Corp Executives Sell Shares to Cover Taxes - TradingView — Track All Markets
Lake Street Sticks to Their Buy Rating for Genelux Corp. (GNLX) - The Globe and Mail
Genelux price target raised to $20 from $10 at Maxim - MSN
Genelux (NASDAQ:GNLX) Director Sells $50,000.00 in Stock - MarketBeat
Genelux (GNLX) Stock Analysis Report | Financials & Insights - Benzinga
GENELUX Corp Director Thomas John Sells 10,000 Shares - TradingView
Dir Thomas Sells 10,000 ($50K) Of Genelux Corp [GNLX] - TradingView
Wall Street analysts’ outlook for Genelux Corp (GNLX) - Setenews
Global Retirement Partners LLC Acquires Shares of 228,676 Genelux Corporation $GNLX - MarketBeat
MAI Capital Management Boosts Holdings in Genelux Corporation $GNLX - MarketBeat
Genelux Corporation Executives to Participate in Fireside Chat at Piper Sandler 37th Annual Healthcare Conference - Quiver Quantitative
Genelux (NASDAQ: GNLX) sets Dec. 3 fireside chat at Piper Sandler 37th Conference - Stock Titan
Genelux Corp. Advances Phase 2 Study in NSCLC with Promising New Treatment - MSN
What risks investors should watch in Genelux Corporation stockForecast Cut & Daily Technical Forecast Reports - newser.com
Genelux Corporation's (NASDAQ:GNLX) 16% loss last week hit both individual investors who own 58% as well as institutions - Sahm
Genelux initiated with a Buy at Titan Partners - MSN
Combining machine learning predictions for Genelux Corporation2025 Breakouts & Breakdowns & Weekly Breakout Opportunity Watchlist - newser.com
What momentum indicators show for Genelux Corporation stockSwing Trade & Expert Verified Stock Movement Alerts - newser.com
What valuation multiples suggest for Genelux Corporation stockWall Street Watch & Accurate Entry/Exit Alerts - newser.com
Will Genelux Corporation stock benefit from AI adoptionWeekly Trade Recap & High Return Trade Guides - newser.com
Can Genelux Corporation stock double in next 5 years2025 Short Interest & Reliable Price Action Trade Plans - newser.com
Is Genelux Corporation stock attractive after correctionWatch List & Safe Entry Point Identification - newser.com
How hedge fund analytics apply to Genelux Corporation stock2025 Price Targets & Smart Swing Trading Techniques - newser.com
Will Genelux Corporation see short term momentumJuly 2025 Analyst Calls & Daily Technical Forecast Reports - newser.com
What MACD signals say about Genelux CorporationTrade Entry Report & Smart Money Movement Tracker - newser.com
Statistical indicators supporting Genelux Corporation’s strengthWeekly Trend Recap & Reliable Price Breakout Signals - newser.com
HC Wainwright Issues Positive Estimate for Genelux Earnings - Defense World
Will Genelux Corporation stock outperform Nasdaq index2025 Price Targets & Risk Controlled Daily Plans - newser.com
Genelux Corp. (GNLX) Receives a Buy from Lake Street - The Globe and Mail
Genelux Corp’s Promising Oncolytic Virus Advancements and Market Potential Drive Buy Rating - TipRanks
Volume spikes in Genelux Corporation stock – what they meanDip Buying & Stepwise Trade Execution Plans - newser.com
Genelux reports Q3 EPS (21c), consensus (21c) - MSN
Promising Clinical Developments in Genelux Corp.’s Olvi-Vec Trials Support Buy Rating - TipRanks
Genelux (GNLX) Projected to Post Earnings on Thursday - MarketBeat
Will Genelux Corporation stock see insider buyingJuly 2025 Chart Watch & High Accuracy Trade Alerts - Fundação Cultural do Pará
Genelux Corporation Provides Q3 2025 Business and Financial Updates, Anticipates Key Clinical Data Next Year - Quiver Quantitative
Genelux Corporation Reports Third Quarter 2025 Financial Results and Provides General Business Updates - Stock Titan
[10-Q] GENELUX Corp Quarterly Earnings Report | GNLX SEC FilingForm 10-Q - Stock Titan
Genelux initiated with a Buy at Lake Street - MSN
Genelux Corp Stock (GNLX) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.08%
0.91%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):